Obsidian Therapeutics, Inc.
OBX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002130606
No open-market purchases or sales by Obsidian Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Obsidian Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Obsidian Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Ross Robert W. | Director | – | Aug 5, 2026 | 1 |
| Norkunas Matthew | Director | – | Aug 5, 2026 | 1 |
| Jagasia Madan | Chief Executive Officer | – | Aug 5, 2026 | 1 |
| Barrett Peter | Director | – | Aug 5, 2026 | 1 |
| Hagen Heidi | Director | – | Aug 5, 2026 | 1 |
| Fardis Maria | Director | – | Aug 5, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.